Skip to main content
Top
Published in: Reactions Weekly 1/2021

01-11-2021 | Neutropenia | Case report

Cisplatin/etoposide

Febrile neutropenia and grade IV neutropenia: 2 case reports

Published in: Reactions Weekly | Issue 1/2021

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Liu C, et al. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study. Thoracic Cancer 12: 1154-1161, No. 8, Apr 2021. Available from: URL: http://doi.org/10.1111/1759-7714.13883 Liu C, et al. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study. Thoracic Cancer 12: 1154-1161, No. 8, Apr 2021. Available from: URL: http://​doi.​org/​10.​1111/​1759-7714.​13883
Metadata
Title
Cisplatin/etoposide
Febrile neutropenia and grade IV neutropenia: 2 case reports
Publication date
01-11-2021
Publisher
Springer International Publishing
Keyword
Neutropenia
Published in
Reactions Weekly / Issue 1/2021
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-06066-y

Other articles of this Issue 1/2021

Reactions Weekly 1/2021 Go to the issue

Case report

Gabapentin

Case report

Sulfadiazine

Case report

Multiple drugs

Case report

Tozinameran